Nov 17 (Reuters) - Acorda Therapeutics Inc
* Acorda announces royalty monetization transactions for $53 million
* Acorda Therapeutics - A $40 million royalty monetization with healthcare royalty partners and a $13 million royalty monetization with H. Lundbeck A/S
* Acorda Therapeutics Inc - In return for payment to Acorda, HCR obtains right to receive royalty revenue on Fampyra payable by Biogen
* Acorda - H. Lundbeck, Acorda amended license agreement for selincro to eliminate future royalty, milestone obligations on sale of Selincro outside U.S.
* Acorda Therapeutics Inc - Transaction does not include potential future milestones to be paid by Biogen Source text for Eikon: Further company coverage: